PPD claims that the new location enhances its ability to deliver a full range of clinical research and development services in China.
Last year, PPD expanded its Phase II-IV clinical development, data management, biostatistics, quality assurance and global regulatory services in Asia Pacific and added more than 300 employees through its acquisition of Excel PharmaStudies.
The new office unites PPD and Excel employees based in Beijing in one facility.
PPD clinical development vice president in Asia Pacific Simon Britton said that the opening of the new office further demonstrates their commitment to investing in China, which continues to be an increasingly important, high-growth area for clinical research.
“The new facility provides us a solid foundation for continued growth in this country and across Asia Pacific to meet the growing needs of our clients,” Britton said.